For years, testosterone replacement therapy has been an important treatment option for men with low testosterone (hypogonadism). Recently, the FDA announced updates to testosterone therapy prescribing information that reflect the latest scientific research, giving both patients and physicians clearer guidance when considering treatment.
What’s Changing?
After reviewing new clinical studies and years of additional research, the FDA has recommended several important updates to testosterone therapy product labels.
1. Updated Guidance for Men with Low Testosterone
Previous labeling stated that the safety and effectiveness of testosterone therapy had not been established for men experiencing age-related declines in testosterone without a specific underlying medical condition.
Based on newer evidence, including large clinical trials, the FDA has determined that this limitation is no longer supported by the current science. This change provides physicians with more flexibility when evaluating whether testosterone therapy may benefit appropriate patients.
Reassessing Cardiovascular Safety
One of the biggest concerns surrounding testosterone therapy has been whether it increases the risk of heart attack or stroke.
A landmark clinical study known as the TRAVERSE Trial, which followed more than 5,200 men, found no significant increase in major cardiovascular events among men receiving testosterone therapy compared to those who did not.
While every patient’s health is unique, these findings provide additional reassurance that testosterone therapy can be used safely in appropriately selected patients under physician supervision.
Updated Information About Prostate Health
The FDA is also revising guidance related to prostate cancer.
Current labeling broadly warns against testosterone therapy in men with known or suspected prostate cancer. Under the proposed updates, testosterone therapy would generally be avoided only in men with metastatic prostate cancer.
What About Enlarged Prostate (BPH)?
Many men considering testosterone therapy also have benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.
Previous warnings suggested testosterone therapy could worsen urinary symptoms. However, current evidence indicates that men with mild to moderate BPH generally do not experience worsening symptoms while on testosterone therapy.
Patients with more severe urinary symptoms should continue to be monitored closely throughout treatment.
What This Means for Patients
The FDA’s updated recommendations reflect how medical knowledge continues to evolve. Rather than changing who should receive testosterone therapy, these updates provide patients with more accurate information about the potential benefits and risks.
If you’re experiencing symptoms of low testosterone—including fatigue, decreased energy, reduced libido, loss of muscle mass, or difficulty concentrating—it may be worth discussing whether testosterone testing and treatment are appropriate for you.
At Conrad Pearson Clinic, our urology specialists evaluate each patient individually, considering hormone levels, overall health, prostate health, and treatment goals before recommending testosterone replacement therapy. Careful monitoring throughout treatment helps ensure therapy remains both safe and effective.
Schedule a Testosterone Evaluation
If you think low testosterone may be affecting your quality of life, the experienced providers at Conrad Pearson Clinic can help determine whether testosterone replacement therapy is right for you. Our team stays current with the latest clinical evidence and national guidelines to provide personalized care for every patient.
